CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 182 enrolled
Drug / intervention
Ipilimumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02545075
NCT02545075Phase 3Completed
CompareCT.gov

A Randomized, Open-Label, Two-arm, Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine

Bristol-Myers Squibb·interventional·Posted Sep 9, 2015·Updated May 19, 2020

In Brief

A Phase 3 clinical trial evaluating Ipilimumab and Dacarbazine for Melanoma. Completed, enrolled 182 participants across 8 sites.

Detailed Summary

The purpose of this study is to determine whether Ipilimumab will extend the life of chinese patients with Chemotherapy Naive Stage IV Melanoma more than Dacarbazine as well as to examine safety in this patient population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 9, 2015
Enrollment StartOct 31, 2015
Primary CompletionApr 19, 2019
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 10.8 years ago

Interventions

Ipilimumabdrug

Dacarbazinedrug